Drug Interactions between gabapentin and Malarone
This report displays the potential drug interactions for the following 2 drugs:
- gabapentin
- Malarone (atovaquone/proguanil)
Interactions between your drugs
No interactions were found between gabapentin and Malarone. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
gabapentin
A total of 270 drugs are known to interact with gabapentin.
- Gabapentin is in the drug class gamma-aminobutyric acid analogs.
-
Gabapentin is used to treat the following conditions:
- Alcohol Use Disorder (off-label)
- Alcohol Withdrawal (off-label)
- Anxiety (off-label)
- Back Pain
- Benign Essential Tremor (off-label)
- Bipolar Disorder (off-label)
- Burning Mouth Syndrome (off-label)
- Carpal Tunnel Syndrome (off-label)
- Chronic Kidney Disease-Associated Pruritus (off-label)
- Chronic Pain
- Cluster-Tic Syndrome (off-label)
- Cough (off-label)
- Diabetic Peripheral Neuropathy (off-label)
- Epilepsy
- Erythromelalgia (off-label)
- Fibromyalgia (off-label)
- Hiccups (off-label)
- Hot Flashes (off-label)
- Hyperhidrosis (off-label)
- Insomnia (off-label)
- Lhermitte's Sign (off-label)
- Migraine (off-label)
- Nausea/Vomiting, Chemotherapy Induced (off-label)
- Neuropathic Pain (off-label)
- Occipital Neuralgia (off-label)
- Pain (off-label)
- Periodic Limb Movement Disorder (off-label)
- Peripheral Neuropathy (off-label)
- Postherpetic Neuralgia
- Postmenopausal Symptoms (off-label)
- Primary Orthostatic Tremor (off-label)
- Pruritus (off-label)
- Pudendal Neuralgia (off-label)
- Reflex Sympathetic Dystrophy Syndrome (off-label)
- Restless Legs Syndrome (off-label)
- Seizures
- Small Fiber Neuropathy (off-label)
- Spondylolisthesis (off-label)
- Syringomyelia (off-label)
- Transverse Myelitis (off-label)
- Trigeminal Neuralgia (off-label)
- Vulvodynia (off-label)
Malarone
A total of 123 drugs are known to interact with Malarone.
- Malarone is in the drug class antimalarial combinations.
- Malarone is used to treat the following conditions:
Drug and food interactions
atovaquone food
Applies to: Malarone (atovaquone / proguanil)
ADJUST DOSING INTERVAL: Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone. In 16 healthy volunteers, administration of a single 750 mg dose of atovaquone suspension following a standard breakfast (23 g fat: 610 kCal) resulted in an approximately 3.4-fold increase in the mean peak plasma concentration (Cmax) and a 2.5-fold increase in the mean area under the plasma concentration-time curve (AUC) of atovaquone compared to administration following an overnight fast. In a study consisting of 19 HIV-infected volunteers receiving atovaquone suspension 500 mg/day, Cmax and AUC of atovaquone increased by 72% and 66%, respectively, in the fed state relative to the fasting state.
MANAGEMENT: To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day. Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.
References (3)
- (2001) "Product Information. Mepron (atovaquone)." Glaxo Wellcome
- (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
gabapentin food
Applies to: gabapentin
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.